Cullinan Therapeutics (CGEM) Net Equity Issued and Repurchased (2020 - 2024)

Cullinan Therapeutics' Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $262.7 million for Q2 2024.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $262.7 million in Q2 2024; TTM through Sep 2025 was $262.7 million, a 0.0% change from a year earlier, with the FY2024 full-year figure at $262.7 million, up 14291.89% from the prior year.
• Net Equity Issued and Repurchased improved to $262.7 million in Q2 2024 per CGEM's latest filing, from $1.8 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $262.7 million in Q2 2024 and bottomed at -$800000.0 in Q2 2022.
• The 5-year median for Net Equity Issued and Repurchased is $1.8 million (2023), against an average of $31.7 million.
• Across the five-year window, Net Equity Issued and Repurchased surged 237.75% in 2021 and dropped 12.1% in 2022, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $800000.0 in 2020, then jumped by 237.75% to $2.7 million in 2021, then fell by 12.1% to $2.4 million in 2022, then retreated by 23.16% to $1.8 million in 2023, then soared by 14291.89% to $262.7 million in 2024.
• Per Business Quant, the three latest CGEM Net Equity Issued and Repurchased figures stand at $262.7 million (Q2 2024), $1.8 million (Q1 2023), and $2.4 million (Q4 2022).